Results 101 to 110 of about 79,249 (245)

Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences [PDF]

, 2015
Herbal medicines are currently in high demand, and their popularity is steadily increasing. Because of their perceived effectiveness, fewer side effects and relatively low cost, they are being used for the management of numerous medical conditions ...
Horie, Toshiharu, Oga, Enoche Florence, Sekine, Shuichi, Shitara, Yoshihisa   +3 more
core   +1 more source

The Promoting Angiogenesis and Its Clinical Significance of CD33+Myeloid Derived Suppressor Cells Derived From Small Cell Lung Cancer

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Background Myeloid‐derived suppressor cells (MDSCs) are important tumor microenvironment components in small cell lung cancer (SCLC). We successfully identified MDSCs expressing the surface marker CD33 in SCLC; nonetheless, whether CD33+MDSCs promote SCLC angiogenesis remains unclear.
Heran Cui, Jingjing Liu, Peiyan Zhao, Yan Liu, Shaowei Lan, Xueli Jiang, Hui Li   +6 more
wiley   +1 more source

Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward [PDF]

, 2019
Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to
Abd-Rabou, Anitha, Arias, Atrián-Blasco, Berners-Price, Bertrand, Carrillo, Chandran, Chibaudel, Clingan, DiGiulio, Esin, Gao, Gasser, Hoste, Li, Liu, Liu, Luo, Miura, Mohana, Moloney, Nadzri, Nisa, Nivethaa, Nunes, Rambabu, Rengaraj, Saǧir, Shaima, Shen, Subudhi, Sun, Tummala, Wang, Yu, Zhang, Zhang, Zhu, Álvarez   +39 more
core   +1 more source

Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice

Frontiers in Pharmacology, 2019
Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a formulation containing microbubble-microdroplet clusters (PS101) together with a regular medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue.
Nigel Bush, Andrew Healey, Anant Shah, Gary Box, Vladimir Kirkin, Spiros Kotopoulis, Svein Kvåle, Per Christian Sontum, Jeffrey Bamber   +8 more
doaj   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Evaluation of pomegranate rind (Punica granatum) hydroethanolic extract on blood parameters in male mice treated by Irinotecan Hcl

Armaghane Danesh Bimonthly Journal, 2015
Background & aim: Irinotecan Hcl is the first order drug for some neoplasm treatment in patients. Irinotecan Hcl has side effects on blood such as anemia and leukopeny.
N Mirazi, Sh Nosrati, A Hosseini
doaj  

Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer [PDF]

, 2010
We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients.
Akashi, Isao, Ashizawa, Tatsuto, Hama, Kouichirou, Hirano, Toshihiko, Iwahori, Tohru, Iwamoto, Hitoshi, Jyojima, Yoshimaro, Kihara, Yuu, Konnno, Osamu, Nagao, Takeshi, Nakamura, Yuuki, Segawa, Mai, Takeuchi, Hironori, Yokoyama, Takayoshi   +13 more
core   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, EarlyView.
What's New? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, EarlyView.
What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source